Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Nephros, Inc.
RIVER EDGE, N.J., May 13, 2014 /PRNewswire/ -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today the first commercial use of its hemodiafiltration ("HDF") system in the United States.
As announced in a separate press release today, DaVita Kidney Care, a division of DaVita HealthCare Partners Inc., is now delivering HDF treatments to select patients in Colorado Springs as part of a six-month trial program. This marks the first commercial delivery of on-line HDF via the Nephros HDF system in the United States. The HDF system is comprised of Nephros' FDA-cleared OLpur MD220 Hemodiafilter and Nephros' OLpur H2H Hemodiafiltration Module. Nephros' OLpur MD220 Hemodiafilter is designed expressly for HDF therapy that employs Nephros's proprietary Mid-Dilution Hemodiafiltration technology. Nephros's OLpur H2H Hemodiafiltration Module is indicated for use with a UF controlled hemodialysis machine that provides ultrapure dialysate in accordance with current ANSI/AAMI/ISO standards, for treatment of patients with chronic renal failure.
"Nephros offers the only FDA cleared on-line HDF therapy available in the U.S., and I am proud that select patients in this country are now being treated with this important therapy," said John C. Houghton, President & CEO of Nephros, Inc. "Today's announcement represents the first product placement in Nephros' ongoing limited launch of its HDF system. In parallel, Nephros continues to evaluate opportunities to leverage the resources of a strategic partner to most effectively expand into the broader market."
About Chronic Kidney Disease
26 million American adults have Chronic Kidney Disease (CKD) and millions of others are at increased risk. CKD is a progressive disease which ultimately leads to kidney failure. There are more than half a million patients whose kidneys have failed requiring them to seek treatment. Of this, approximately 370,000 are receiving hemodialysis and this number is growing year on year. In 2011, the total medical care costs for Chronic Renal Failure reached an estimated $49.2 billion. On-line HDF represents an alternative treatment option for chronic renal failure with potential advantages over standard hemodialysis. On-line HDF is commonly practiced in Europe but the Nephros HDF system is the only FDA cleared device available in the U.S.
About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Our filters, which we call ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood.
We were founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis (HD). We have extended our filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.
Presently, we offer ultrafilters for sale to customers in four markets:
For more information about Nephros, please visit the company's website at www.nephros.com.
Certain statements in this press release constitute "forward-looking statements". Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward looking statements. Factors that may cause such differences include, but are not limited to, the risks that:
More detailed information about the company and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and our other periodic reports filed with the SEC. We urge you to read those documents free of charge at the SEC's web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
©2012 PR Newswire. All Rights Reserved.